Gastrointestinal stromal tumor historical perspective

Jump to navigation Jump to search

Gastrointestinal stromal tumor Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Epidemiology and Demographics

Risk Factors

Screening

Differentiating Gastrointestinal stromal tumor from other Diseases

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Gastrointestinal stromal tumor historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Gastrointestinal stromal tumor historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Gastrointestinal stromal tumor historical perspective

CDC on Gastrointestinal stromal tumor historical perspective

Gastrointestinal stromal tumor historical perspective in the news

Blogs on Gastrointestinal stromal tumor historical perspective

Directions to Hospitals Treating Gastrointestinal stromal tumor

Risk calculators and risk factors for Gastrointestinal stromal tumor historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Akshun Kalia M.B.B.S.[2]

Overview

Prior to the advent and use of electron microscopy, gastrointestinal stromal tumors (GIST) were classified as smooth muscle tumors such as leiomyomas or leiomyosarcomas. In 1983, Mazur and Clark and Schaldenbrand and Appleman in 1984 were the first to describe gastrointestinal stromal tumors as an independent entity of intra-abdominal tumors that were neither carcinomas nor exhibit histologic features of smooth muscle or nerve cells. In 1998, Kindblom et al described the origin of GIST as pluripotential mesenchymal stem cells which were programmed to differentiate into the interstitial cell of Cajal. In 1998 Hirota and others were the first to describe c-kit (proto-oncogene) mutations as the cause of GIST. In 2001, Joensuu was the first to report successful treatment of patients with advanced GIST on molecular-targeted therapy (imatinib).

Historical Perspective

The historical perspective of gastrointestinal stromal tumors (GIST) is as follow: [1][2][3]

References

  1. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM (1998). "Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal". Am. J. Pathol. 152 (5): 1259–69. PMC 1858579. PMID 9588894.
  2. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y (1998). "Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors". Science. 279 (5350): 577–80. PMID 9438854.
  3. Mazur MT, Clark HB (1983). "Gastric stromal tumors. Reappraisal of histogenesis". Am. J. Surg. Pathol. 7 (6): 507–19. PMID 6625048.


Template:WikiDoc Sources